

# Target Market Statement & Fair Value Assessment Outcome

Nexus Underwriting Limited has undertaken a Fair Value Assessment in accordance with our product governance obligations. This document is intended to provide a summary of the target market & fair value assessment only, please refer to the policy documentation for full details of the coverage provided by the product.

For use by distributors, not intended to be circulated to customers.

<b>Product name</b>	Fund Directors & Officers
<b>Manufacturer</b>	Nexus Underwriting Limited acting on behalf of certain underwriters, details of which will be provided at the time of quotation.

## What is this product

The product provides Financial Institutions Directors and Officers Liability (including Side A and DIC/DIL) insurance to SME and mid-market and large sized private and publicly traded funds.

## What customer need is met by this product?

D&O affords cover for legal defence costs and damages awards following claims against Directors and Officers in their capacity as directors and officers of the fund, brought by various third parties. This helps to protect the assets of the Directors and Officers and the fund, where the fund has indemnified or agreed to indemnify the Director or Officer.

## Who is this product designed for?

- SME, mid-market and large funds that are privately owned or listed on a stock exchange.
- Companies domiciled in the United Kingdom or in other countries as agreed and where the underwriters are licensed/authorised to provide the cover (details of which will be provided at the time of quotation).
- Policyholders for their legal liability occurring anywhere in the world (unless otherwise stated at the time of quotation).

## Who is this product not designed to support, or are there any features that you should be aware of when offering this product to your customers?

This product is not suitable for:

- Policyholders acting outside of the trade or profession as declared to and agreed with us.
- Sole traders and unincorporated partnerships who are not subject to the Companies Act or similar.
- Policyholders that may already benefit from cover provided to their parent company, or otherwise granted coverage from a manager policy.
- Consumers (as defined by the FCA).

The policy will not cover:

- Prior or pending litigation occurring before the policy starts, or circumstances known to the policyholder before the policy starts which reasonably could be expected to give rise to a claim.

- Illegal acts where this is adjudicated as such in a recognised court, or where the insured formally admits to the illegal act.

Terms and conditions are agreed with any one client on a case-by-case basis and there may be instances where the policy may not cover any claim arising out of (for example); money laundering, pollution, professional services, bodily injury / property damage and intellectual property rights infringement.

Please refer to the policy documentation for full details of the insurance cover as well for details of any limitations and/or exclusions.

### How is this product sold?

This product should be distributed by FCA regulated brokers on an advised basis by face to face or electronic communication methods.

The product runs for a duration of 12 months and it can be provided on a primary, excess of loss, coinsurance or 100% basis.

### Fair Value Review

This product has been subject to our product review process and signed off as representing fair value to customers.

- When carrying out our review we have assessed at a minimum;
- That the insurance product remains consistent with the needs of the identified target market;
- That the intended distribution strategy remains appropriate;
- That the remuneration does not have a negative impact on the value of the product.

When assessing value, we have considered appropriate available information including data in respect of; claims and product performance, complaints, remuneration, service levels and the outputs of monitoring checks.

Our product governance and oversight arrangements require all insurance products that we manufacture to be reviewed at least every 12 months and more frequently where the potential risk associated with the product makes it appropriate to do so. The risk rating will determine the product approval and review procedure that is followed, as well as the minimum management information collected to ensure appropriate oversight of how the product is performing.

### Other information which may be relevant to distributors

The standard policy terms and conditions are often tailored by the use of endorsements which expand or restrict coverage based on the quality of the individual risk. Endorsements are clearly displayed on quote and policy documents. This is standard market practice.

We require distributors to provide additional information on remuneration or services on an annual basis. You should consider the impact of any additional remuneration and services on the value of the product, including:

- Any additional fees that you charge a customer;
- Any ancillary products sold alongside the product which may affect the product's value; or
- Any duplicate cover.

Following the UK's departure from the EU, European risks are handled by our underwriters on a secondment agreement with the UK branch of our French entity Nexus Europe Sarl.

Claims may be handled by a third-party administrator on behalf of the insurer.	
<b>Additional Policy Documentation</b>	<p>This document is to be read in conjunction with the following product documentation:</p> <ul style="list-style-type: none"> <li>• Policy Wording</li> <li>• Policy Summary</li> </ul>
<b>Fair Value Assessment Outcome</b>	
<p>Following our product value assessment, we consider that this product remains suitable for the target market and provides fair value.</p> <p>Where individual distribution arrangements have been identified that could mean customers are at a greater risk of not receiving fair value from the insurance product, distributors have been contacted directly.</p>	
<b>Date Fair Value assessment completed</b>	September 2022
<b>Expected date of next assessment</b>	Within 12 months of this assessment